Drugs / B/F/TAF
last change Jul 2026 re-read 2 minutes ago

B/F/TAF

Developed for
HIV infectious disease
Investigated by
Gilead Sciences

Trials 1 · a red edge is where a trial was stopped

2027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT07708727 Jul 2026 → Oct 2030 expected HIV infectious disease Gilead Sciences Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as B/F/TAF ClinicalTrials.gov intervention name — accepted as the source's own label NCT07708727
Route Oral “Administered orally” NCT07708727